Spruce Biosciences Inc banner

Spruce Biosciences Inc
NASDAQ:SPRB

Watchlist Manager
Spruce Biosciences Inc Logo
Spruce Biosciences Inc
NASDAQ:SPRB
Watchlist
Price: 51.075 USD -3.08% Market Closed
Market Cap: $138m

Wall St Price Targets

SPRB Price Targets Summary
Spruce Biosciences Inc

Wall Street analysts forecast SPRB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRB is 190.332 USD with a low forecast of 141.4 USD and a high forecast of 297.15 USD.

Lowest Forecast
Price Target
141.4 USD
177% Upside
Average Forecast
Price Target
190.332 USD
273% Upside
Highest Forecast
Price Target
297.15 USD
482% Upside
Spruce Biosciences Inc Competitors:
Price Targets
LGI
Lgi Ltd
31% Upside
RLMD
Relmada Therapeutics Inc
99% Upside
VAC
Pierre et Vacances SA
27% Upside
AMAL
Amalgamated Bank
14% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-73%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-73%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SPRB's stock price target?
Price Target
190.332 USD

According to Wall Street analysts, the average 1-year price target for SPRB is 190.332 USD with a low forecast of 141.4 USD and a high forecast of 297.15 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett